Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

MaxCyte touts strategic platform license deal with Kamau Therapeutics

Mon, 16th Sep 2024 10:33

(Alliance News) - MaxCyte Inc on Monday celebrated the signing of a strategic platform license agreement with Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company.

MaxCyte is a Rockville, Maryland-based provider of cell engineering platform technologies.

According to the terms of the deal, Kamau gets non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform.

In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.

"Bringing this groundbreaking gene therapy research into the clinic requires a robust manufacturing process and the ability to scale," said Chief Executive Officer Maher Masoud.

"By partnering with us, Kamau gains access to our commercially validated Flow Electroporation technology as well as technical, regulatory and scientific support. This enables them to optimize their clinical manufacturing process, mitigate risks and expedite the progression of their lead product candidate through clinical phases to deliver this potential cure to patients living with SCD."

Shares in MaxCyte were trading 2.9% higher at 308.60 pence each in London on Monday morning.

By Holly Beveridge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
8 Nov 2024 14:41

MaxCyte third-quarter profit falls amid surging costs

(Alliance News) - MaxCyte Inc on Thursday said profit fell in the third quarter despite revenue growth, as costs increase more than 80%.

30 Oct 2024 15:08

UK earnings, trading statements calendar - next 7 days

10 Oct 2024 13:23

MaxCyte appoints new chief commercial officer

(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Ali Soleymannezhad as its new chief commercial officer on Thursday, e...

16 Sep 2024 11:22

MaxCyte enters licence agreement with Kamau Therapeutics

(Sharecast News) - Cell engineering technology company MaxCyte announced a strategic platform licence agreement with Kamau Therapeutics, a clinical-st...

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.